Fig. 2: Peripheral immune cells into the SN and the striatum 3 months after LPS administration. | npj Parkinson's Disease

Fig. 2: Peripheral immune cells into the SN and the striatum 3 months after LPS administration.

From: Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human alpha synuclein

Fig. 2

a Bar plots of the percentage of CD45highCD3+ T cells in the SNpc (top) and the striatum (bottom). (n = 5 SAL WT, n = 5 LPS WT, n = 6 SAL Snca+/+, n = 6 LPS Snca+/+; Ordinary two-way ANOVA for Genotype vs Treatment; SNpc: Interaction, F (1, 18) = 11.58, p = 0.0032; Genotype, F (1, 18) = 25.14, p < 0.0001; Treatment, F (1, 18) = 14.07, p = 0.0015; ***p < 0.001, ****p < 0.0001, with Bonferroni’s post hoc multiple comparisons test; striatum: Interaction, F (1, 18) = 2.041; Genotype, F (1, 18) = 15.05, p = 0.0011; Treatment, F (1, 18) = 44.63, p < 0.0001; *p < 0.05, **p < 0.01, ****p < 0.0001, with Bonferroni’s post hoc multiple comparisons test). b Bar plots of the percentage of CD45highCD45RA+ B cells in the SNpc (top) and the striatum (bottom). (n = 5 SAL WT, n = 5 LPS WT, n=6 SAL Snca+/+, n = 6 LPS Snca+/+; Ordinary two-way ANOVA for Genotype vs Treatment; SNpc: Interaction, F (1, 18) = 0.02012; striatum: Interaction, F (1, 18) = 1.916). c Bar plots of the percentage of CD45highCD161+NK cells in the SNpc (top), while, in the striatum (bottom), a significant genotype effect in Snca+/+ compared to WT groups is shown, independent from treatment. (n = 5 SAL WT, n = 5 LPS WT, n = 6 SAL Snca+/+, n = 6 LPS Snca+/+; Ordinary wo-way ANOVA for Genotype vs. Treatment; SNpc: Interaction F (1, 18) = 0.01421; striatum: Interaction, F (1, 18) = 0.01596; Genotype, F (1, 18) = 33.17, p < 0.0001; Treatment, F (1, 18) = 2.033; *p < 0.05, **p < 0.01, ***p < 0.001, with Bonferroni’s post hoc multiple comparisons test).

Back to article page